The Botswana government has assured the public that the country’s antiretroviral (ARV) medication program will not be affected by the recent suspension of U.S. foreign aid to the health sector.
In a statement issued by the Ministry of Health, officials confirmed that while U.S.-funded civil society organizations (CSOs) implementing various health programs have been instructed to suspend their operations immediately, the supply of ARVs remains secure. This is because the Botswana government directly procures ARV medication, ensuring continuity in treatment for people living with HIV/AIDS.
The U.S. has historically played a crucial role in supporting Botswana’s health sector through programs such as the President’s Emergency Plan for AIDS Relief (PEPFAR), the U.S. Agency for International Development (USAID), and the Centers for Disease Control and Prevention (CDC). Since 2003, Botswana has received more than one billion pula in health-related aid, helping the country surpass the UNAIDS 95-95-95 targets.
Despite the challenges posed by the aid suspension, the Ministry of Health emphasized its commitment to engaging with all stakeholders, including the U.S. Embassy, to explore ways to sustain affected programs. However, officials reiterated that access to ARVs remains a priority and will not be disrupted.
More updates are expected as discussions with stakeholders continue.
